Regeneron
Trending Articles
Related Content
Ingredients
Therapeutic: odronextamab for blood cancers
Follicular lymphoma (FL) is a slow-growing form of B cell non-Hodgkin lymphoma that is usually in the advanced stage by diagnosis. Median survival is typically 8–15 years, but none of the current therapy options are curative and most patients will relapse within 5 years
Regulatory
Sanofi and Regeneron announce Marketing Authorisation Application for Dupixent (dupilumab) accepted for review by the EMA
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for Dupixent® (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy